RAC1 and breast cancer: Our data suggest that combined inhibition of BRD4-RAC1 pathways represents a potential therapeutic approach in different molecular subtypes of breast cancer and highlights the importance of RAC1-BRD4 signaling in breast tumorigenesis and development by targeting disruption of C-MYC/G9a/FTH1 axis and down regulation of HDAC1.